Pharmaceutical - Pharmaceutical, Posidur

Filter

Current filters:

PharmaceuticalPosidur

Popular Filters

Pfizer to finally drop Remoxy development

27-10-2014

Shares of Durect Corp plunged 42.9% to $0.79 after it revealed that pharma giant Pfizer has decided to…

DurectLicensingNeurologicalPain TherapeuticsPfizerPharmaceuticalPosidurRemoxyUSA

FDA says Durect’s pain relief drug Posidur needs additional safety studies

FDA says Durect’s pain relief drug Posidur needs additional safety studies

13-02-2014

US drugmaker Durect Corp says that the US Food and Drug Administration has issued a Complete Response…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

US FDA accepts DURECT's NDA for Posidur

20-06-2013

DURECT Corp (Nasdaq: DRRX) says that the New Drug Application for its investigational product Posidur…

DurectNeurologicalNorth AmericaPharmaceuticalPosidurRegulation

Hospira returns Posidur rights to DURECT

02-04-2012

DURECT Corp (Nasdaq: DRRX) says that fellow USA-based that Hospira (NYSE: HSP) has given notice that…

DurectHospiraLicensingNeurologicalNorth AmericaPharmaceuticalPosidur

Back to top